PNC Financial Services Group Inc. Has $141,000 Stock Holdings in Elanco Animal Health Incorporated $ELAN

PNC Financial Services Group Inc. lifted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 14.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,404 shares of the company’s stock after buying an additional 1,641 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Elanco Animal Health were worth $141,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in shares of Elanco Animal Health by 6.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company’s stock worth $216,774,000 after purchasing an additional 1,074,274 shares during the period. Yousif Capital Management LLC bought a new position in shares of Elanco Animal Health in the first quarter worth about $119,000. Wealth Enhancement Advisory Services LLC acquired a new position in Elanco Animal Health during the 1st quarter valued at $111,000. SG Americas Securities LLC acquired a new position in Elanco Animal Health during the 1st quarter valued at $891,000. Finally, GAMMA Investing LLC raised its stake in Elanco Animal Health by 1,743.8% during the 1st quarter. GAMMA Investing LLC now owns 12,390 shares of the company’s stock valued at $130,000 after purchasing an additional 11,718 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Piper Sandler upped their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, August 11th. UBS Group increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Stifel Nicolaus increased their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Wall Street Zen upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Elanco Animal Health Stock Down 1.4%

Shares of NYSE:ELAN opened at $17.72 on Tuesday. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.08. The company’s 50-day moving average price is $14.81 and its two-hundred day moving average price is $12.31. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The firm has a market cap of $8.80 billion, a P/E ratio of 20.60, a P/E/G ratio of 3.33 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the prior year, the firm earned $0.30 EPS. The company’s revenue was up 4.8% on a year-over-year basis. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.